Latest News

Characterization of early-start TRAILBLAZER-ALZ 2 participants who required continued donanemab in the long-term extension suggests durable clinical benefit with fewer cumulative doses.

The professor at MedStar Georgetown University Hospital spoke about a live session that featured patient evaluations and injection demonstrations designed to help clinicians refine treatment strategies for dystonia, spasticity, sialorrhea, and other neurologic conditions. [WATCH TIME: 2 minutes]

Early data from the Clinical Nurse Navigator program show that more than 99% of patients with Parkinson's disease reaching a first optimization dose of continuous subcutaneous apomorphine infusion did so without antiemetic pretreatment.

At ATMRD 2026, the director of Movement Disorders at Banner Sun Health Research Institute discussed emerging biomarker and imaging technologies, the importance of clinical diagnostic expertise, and the evolving treatment landscape for atypical parkinsonian disorders and adult-onset ataxias.

Here's some of what is coming soon to NeurologyLive® this week.

Real-world survey data suggest deutetrabenazine treatment may be associated with improvements in patient- and caregiver-reported quality-of-life outcomes among individuals with Huntington disease chorea.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Brain insulin resistance!

Exploratory post hoc data suggest prompt pimavanserin initiation within 6 to 12 months of PDP onset may yield a more favorable symptom trajectory, though prospective confirmation is needed.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 5, 2026.

As the MS community reflects on World MS Day, Alla Wilson, a clinical ambulatory pharmacist at Shields Health Solutions, discusses how integrated specialty pharmacy models can improve treatment access, adherence, and patient-reported outcomes for multiple sclerosis.

European regulators have expanded atogepant’s label to include acute migraine treatment, supported by phase 3 data showing significant pain freedom and sustained relief versus placebo.

The assistant professor of neurology at NYU Grossman School of Medicine discussed how optical coherence tomography can support the 2024 McDonald Criteria for multiple sclerosis at CMSC 2026.

12-montn interim findings from an ongoing phase 1/2 study showed up to 69% reductions in mutant huntingtin protein and favorable cUHDRS trends with the investigational oral RNA-splicing modifier SKY-0515.